{"doi":"10.1111/dmcn.15406","title":"Child neurology telemedicine: Analyzing 14 820 patient encounters during the first year of the <scp>COVID</scp> ‐19 pandemic","abstract":"AIM: To determine the long-term impact of telemedicine in child neurology care during the COVID-19 pandemic and with the reopening of outpatient clinics. METHOD: We performed an observational cohort study of 34 837 in-person visits and 14 820 telemedicine outpatient visits across 26 399 individuals. We assessed differences in care across visit types, time-period observed, time between follow-ups, patient portal activation rates, and demographic factors. RESULTS: We observed a higher proportion of telemedicine for epilepsy (International Classification of Diseases, 10th Revision G40: odds ratio [OR] 1.4, 95% confidence interval [CI] 1.3-1.5) and a lower proportion for movement disorders (G25: OR 0.7, 95% CI 0.6-0.8; R25: OR 0.7, 95% CI 0.6-0.9) relative to in-person visits. Infants were more likely to be seen in-person after reopening clinics than by telemedicine (OR 1.6, 95% CI 1.5-1.8) as were individuals with neuromuscular disorders (OR 1.6, 95% CI 1.5-1.7). Self-reported racial and ethnic minority populations and those with highest social vulnerability had lower telemedicine participation rates (OR 0.8, 95% CI 0.8-0.8; OR 0.7, 95% CI 0.7-0.8). INTERPRETATION: Telemedicine continued to be utilized even once in-person clinics were available. Pediatric epilepsy care can often be performed using telemedicine while young patients with neuromuscular disorders often require in-person assessment. Prominent barriers for socially vulnerable families and racial and ethnic minorities persist.","journal":"Developmental Medicine & Child Neurology","year":2022,"id":267732,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":7,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.6058,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2022-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":106384,"name":"Julie Xian","orcid":"0000-0002-0205-0648","position":1,"is_corresponding":false},{"id":106362,"name":"Peter D. Galer","orcid":"0000-0002-6408-0906","position":2,"is_corresponding":false},{"id":632138,"name":"Shridhar Parthasarathy","orcid":"0000-0001-7415-801X","position":3,"is_corresponding":false},{"id":467264,"name":"Alexander K. Gonzalez","orcid":"0000-0002-4402-398X","position":4,"is_corresponding":false},{"id":872853,"name":"Jillian L. McKee","orcid":"0000-0001-9724-0403","position":5,"is_corresponding":false},{"id":319054,"name":"Marisa S. Prelack","orcid":null,"position":6,"is_corresponding":false},{"id":317113,"name":"Mark P. Fitzgerald","orcid":"0000-0002-7121-0705","position":7,"is_corresponding":false},{"id":44516,"name":"Ingo Helbig","orcid":"0000-0001-8486-0558","position":8,"is_corresponding":false},{"id":632141,"name":"Michael C. Kaufman","orcid":"0000-0003-2718-296X","position":0,"is_corresponding":true}],"reference_count":25,"raw_metadata":null,"created_at":"2026-07-19T00:27:06.198948Z","pmid":"38767061","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}